|
Feb 25
|
J&J’s potential neurovascular exit: implications for market dynamics
|
|
Feb 14
|
Terumo Corp (TRUMF) Q3 2025 Earnings Call Highlights: Record Revenue and Strategic Growth Amid ...
|
|
Oct 10
|
Terumo (TRUMY) Is a Great Choice for 'Trend' Investors, Here's Why
|
|
Jul 25
|
Terumo (TRUMY) Unit Reveals WEB 17 Device Effective in Aneurysms
|
|
Jul 23
|
MicroVention Announces Release of CLinical EValuation of WEB™ 17 Device in Intracranial Aneurysms (CLEVER): One Year Effectiveness Results for Ruptured and Unruptured Aneurysms
|
|
Feb 13
|
Terumo Corp. (TRUMY) is on the Move, Here's Why the Trend Could be Sustainable
|
|
Jan 10
|
Recent Price Trend in Terumo Corp. (TRUMY) is Your Friend, Here's Why
|